| Bone Marrow Mast Cell Burden and Serum Tryptase Level as Markers of Response in Patients with Systemic Mastocytosis. | |
| | |
MedLine Citation:
|
PMID: 23278641 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Abstract Two important response criteria in systemic mastocytosis (SM) are the elimination or reduction in the percentage of bone marrow mast cells (MCs), and the reduction of serum tryptase levels. We investigated the accuracy of a single time point reduction of bone marrow MCs and serum tryptase level as response criteria in 50 patients with SM with available serial assessments. Bone marrow MC percentage varied significantly with an average coefficient of variation (CV) of 65% (range, 6%-173%) and 44% of patients having a CV higher than the average. The average CV for serum tryptase level was 19% (range, 0%-96%), with 36% of patients having a CV higher than average. These wide variations in bone marrow MC burden and serum tryptase level were independent of the administration of SM-directed therapy, type of therapy or disease subtype. Furthermore, the achievement of a single time point therapy-induced bone marrow complete response (no histological evidence of malignant bone marrow MCs) did not correlate with tryptase level or symptomatic improvement. In conclusion, the value of single measurement of bone marrow MC percentage and serum tryptase level as response criteria in SM is not supported by clinical data. The incorporation of the assessment of a degree in the reduction of MCs and tryptase, and assessment of response durability, would make response criteria more clinically meaningful. |
| | |
Authors:
|
Alfonso Quintás-Cardama; Matjaz Sever; Jorge Cortes; Hagop Kantarjian; Srdan Verstovsek |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-1-2 |
Journal Detail:
|
Title: Leukemia & lymphoma Volume: - ISSN: 1029-2403 ISO Abbreviation: Leuk. Lymphoma Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-1-2 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9007422 Medline TA: Leuk Lymphoma Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pharmacologic Prophylaxis Regimens for Acute GVHD - Past, Present and Future.
Next Document: Association of A(313)G Glutathione S-transferase P1 germline polymorphism with susceptibility to de ...